$LIANY
LianBio Stock $liany

$liany Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000183128322000075 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$18.67M	$16.29M	$8.889M
YoY Change	29.8%	83.27%	317.52%
% of Gross Profit
Research & Development	$10.58M	$8.258M	$4.655M
YoY Change	38.19%	77.4%	-96.02%
% of Gross Profit
Depreciation & Amortization	$317.0K	$300.0K	$141.0K
YoY Change	28.34%	112.77%	403.57%
% of Gross Profit
Operating Expenses	$29.25M	$24.55M	$13.54M
YoY Change	32.71%	81.25%	-88.62%
Operating Profit		-$24.55M	-$13.54M
YoY Change		81.25%
Interest Expense	$2.083M	$1.405M	$32.00K
YoY Change	2793.06%	4290.63%	-102.47%
% of Operating Profit
Other Income/Expense, Net	$8.536M	$1.253M	$3.000K
YoY Change	-3309.02%	41666.67%	-96.97%
Pretax Income	-$18.63M	-$21.89M	-$13.51M
YoY Change	-16.21%	62.05%	-88.76%
Income Tax	-$350.0K	$6.000K	-$397.0K
% Of Pretax Income
Net Earnings	-$18.28M	-$21.90M	-$13.11M
YoY Change	-13.77%	67.0%	-89.09%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.20	-$0.63
Diluted Earnings Per Share	-$0.17	-$0.20	-$124.6K
COMMON SHARES
Basic Shares Outstanding	108.4M shares	108.4M shares	20.69M shares
Diluted Shares Outstanding		108.4M shares	20.69M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$302.4M	$311.7M	$109.0M
YoY Change	-21.11%	185.95%
Cash & Equivalents	$79.22M	$78.86M	$109.0M
Short-Term Investments	$223.1M	$232.9M
Other Short-Term Assets	$6.000M	$3.024M	$5.583M
YoY Change	-34.63%	-45.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$1.770M	$7.393M
Total Short-Term Assets	$312.8M	$324.2M	$121.0M
YoY Change	-21.74%	167.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.116M	$3.135M	$913.0K
YoY Change	65.57%	243.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.00K	$37.00K	$20.01M
YoY Change	-60.78%	-99.82%
Total Long-Term Assets	$7.187M	$27.60M	$20.92M
YoY Change	-73.08%	31.93%
TOTAL ASSETS
Total Short-Term Assets	$312.8M	$324.2M	$121.0M
Total Long-Term Assets	$7.187M	$27.60M	$20.92M
Total Assets	$320.0M	$351.8M	$141.9M
YoY Change	-24.95%	147.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.453M	$2.019M	$1.639M
YoY Change	-55.03%	23.18%
Accrued Expenses	$19.83M	$17.87M	$12.94M
YoY Change	98.74%	38.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$23.62M	$22.03M	$22.26M
YoY Change	56.47%	-1.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$210.0K	$200.0K	$20.00M
YoY Change	1.94%	-99.0%
Total Long-Term Liabilities	$210.0K	$200.0K	$20.00M
YoY Change	1.94%	-99.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.62M	$22.03M	$22.26M
Total Long-Term Liabilities	$210.0K	$200.0K	$20.00M
Total Liabilities	$26.31M	$45.24M	$86.45M
YoY Change	-32.54%	-47.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$470.5M	-$452.2M
YoY Change	30.62%
Common Stock	$732.5M	$728.9M
YoY Change	2.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$259.9M	$272.8M	$55.48M
YoY Change
Total Liabilities & Shareholders Equity	$320.0M	$351.8M	$141.9M
YoY Change	-24.95%	147.91%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$18.28M	-$21.90M	-$13.11M
YoY Change	-13.77%	67.0%	-89.09%
Depreciation, Depletion And Amortization	$317.0K	$300.0K	$141.0K
YoY Change	28.34%	112.77%	403.57%
Cash From Operating Activities	-$30.71M	-$15.96M	-$38.80M
YoY Change	1.1%	-58.85%	-8.9%
INVESTING ACTIVITIES
Capital Expenditures	$235.0K	-$937.0K	-$92.00K
YoY Change	-129.82%	918.48%	607.69%
Acquisitions
YoY Change
Other Investing Activities	$11.23M	-$37.57M
YoY Change	-107.25%
Cash From Investing Activities	$11.00M	-$38.51M	-$92.00K
YoY Change	-107.06%	41759.78%	607.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.309M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	5.309M
YoY Change	-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-30.71M	-15.96M	-38.80M
Cash From Investing Activities	11.00M	-38.51M	-92.00K
Cash From Financing Activities	0.000	0.000	5.309M
Net Change In Cash	-19.72M	-54.47M	-33.58M
YoY Change	-116.59%	62.22%	-21.17%
FREE CASH FLOW
Cash From Operating Activities	-$30.71M	-$15.96M	-$38.80M
Capital Expenditures	$235.0K	-$937.0K	-$92.00K
Free Cash Flow	-$30.95M	-$15.03M	-$38.71M
YoY Change	4.58%	-61.18%	-9.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001831283
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40947
	dei	Entity Registrant Name EntityRegistrantName	LianBio
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1594670
	dei	Entity Address Address Line1 EntityAddressAddressLine1	103 Carnegie Center Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 309
	dei	Entity Address City Or Town EntityAddressCityOrTown	Princeton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08540
	dei	City Area Code CityAreaCode	609
	dei	Local Phone Number LocalPhoneNumber	486-2308
	dei	Security12b Title Security12bTitle	American Depositary Shares, each representing 1 ordinary share, par value $0.000017100448 per share
	dei	Trading Symbol TradingSymbol	LIAN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	108353831	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78862000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	228182000	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	232866000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	155067000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5117000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10354000	usd
CY2022Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	7393000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	6044000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	324238000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	399647000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	20070000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	20000000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3135000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1882000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4362000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4763000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	51000	usd
CY2022Q3	us-gaap	Assets Assets	351842000	usd
CY2021Q4	us-gaap	Assets Assets	426343000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2019000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3231000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17871000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9976000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1750000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1125000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	387000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	760000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	22027000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15092000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3017000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3709000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	200000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	206000	usd
CY2022Q3	adr	Nonrefundable Research Deposit NonrefundableResearchDeposit	20000000	usd
CY2021Q4	adr	Nonrefundable Research Deposit NonrefundableResearchDeposit	20000000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	45244000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	39007000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000017100448
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000017100448
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2923900005	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	108353831	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	108353831	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2923900005	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107275458	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107275458	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	728915000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	713269000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3844000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	526000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-452249000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-360235000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	272824000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	353562000	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	33774000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	33774000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	306598000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	387336000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	351842000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	426343000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8258000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4655000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49178000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	151038000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16291000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8889000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46930000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22496000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	24549000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	13544000	usd
	us-gaap	Operating Expenses OperatingExpenses	96108000	usd
	us-gaap	Operating Expenses OperatingExpenses	173534000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-24549000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13544000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-96108000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-173534000	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1405000	usd
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	32000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2238000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	171000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1253000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1873000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-189000	usd
CY2022Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-21891000	usd
CY2021Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-13509000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-91997000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-173552000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-397000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1553000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-21897000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-13112000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-92014000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-175105000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2282000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-26000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3096000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	104000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-160000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1274000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24339000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13138000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-96384000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-175001000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.52
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.52
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108353831	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108353831	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20690908	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20690908	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107854547	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107854547	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20549310	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20549310	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	387336000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4669000	usd
CY2022Q1	adr	Apic Due From Related Parties Increase For Cost Recognition APICDueFromRelatedPartiesIncreaseForCostRecognition	1710000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-27726000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1216000	usd
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-98070000	usd
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	364773000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4528000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-42391000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-712000	usd
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	326198000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4739000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-21897000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2442000	usd
CY2022Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	306598000	usd
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	10971231	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	349789000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1674000	usd
CY2021Q1	adr	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	52947	shares
CY2021Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	2940000	usd
CY2021Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	9415000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-61565000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	8000	usd
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11024178	shares
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	352729000	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-148538000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1443000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-100428000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	122000	usd
CY2021Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11024178	shares
CY2021Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	352729000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-247401000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2168000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	5957000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5309000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-13112000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-26000	usd
CY2021Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11024178	shares
CY2021Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	352729000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-253062000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-92014000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-175105000	usd
	adr	Non Cash Share Consideration Issued In Acquisition Of Ipr And D NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD	0	usd
	adr	Non Cash Share Consideration Issued In Acquisition Of Ipr And D NonCashShareConsiderationIssuedInAcquisitionOfIPRAndD	9415000	usd
	adr	Non Cash Operating Lease Expense Benefit NonCashOperatingLeaseExpenseBenefit	354000	usd
	adr	Non Cash Operating Lease Expense Benefit NonCashOperatingLeaseExpenseBenefit	-76000	usd
	us-gaap	Depreciation Depreciation	689000	usd
	us-gaap	Depreciation Depreciation	278000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	13936000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5285000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	481000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1375000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	56000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4794000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3801000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1244000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-14216000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-11000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1091000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2690000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	8197000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	11568000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-248000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1434000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68472000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-133573000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1610000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	159000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	260367000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	181780000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-80197000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-159000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1710000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5309000	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	3000000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	60000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1710000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8249000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2291000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-149250000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-125335000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	248182000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	254350000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98932000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129015000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78862000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109015000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	20070000	usd
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	20000000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98932000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129015000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	523000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1233000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	247000	usd
	adr	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	0	usd
	adr	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	3310000	usd
	adr	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	3310000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	551000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LianBio (“LianBio” or the “Company”) is a global, science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the Cayman Islands in July 2019 and maintains its Chinese headquarters in Shanghai, China. The Company conducts its corporate activities at its United States headquarters located in Princeton, New Jersey. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2021, the Company completed its initial public offering (“IPO”) through an underwritten sale of 20,312,500 American Depositary Shares (“ADSs") representing 20,312,500 ordinary shares at a price of $16.00 per share. Following the close of the IPO, on December 1, 2021, the underwriters partially exercised their option to purchase additional shares and purchased an additional 593,616 ADSs at the IPO price of $16.00 per ADS. The Company received gross proceeds of $334.5 million in connection with the IPO and subsequent exercise of the underwriters’ option and aggregate net proceeds of $304.8 million after deducting underwriting discounts, commissions and other offering expenses.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the IPO, all of the Company’s convertible preferred shares then-outstanding were automatically converted into an aggregate of 64,467,176 ordinary shares and were reclassified into permanent equity. Following the IPO, there were no preferred shares outstanding.</span></div>
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	64467176	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	223393000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(B) Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The only material estimates in the accompanying financial statements are the fair value of warrants, share-based compensation, and share options. Actual results could differ from those used in evaluating these accounting estimates.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (“COVID-19”) outbreak a pandemic. The Company’s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including planned clinical trials. The impact of the COVID-19 pandemic on the Company’s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy continue to be impacted for an extended period, the Company’s results may be materially adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to material credit risk due to the financial position of the banking institutions. The Company has no off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s results of operations involve numerous risks and uncertainties. Factors that could affect the Company’s operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials, uncertainty of regulatory approval of the Company’s potential product candidates, uncertainty of market acceptance of its product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company’s product candidates require approvals from the National Medical Products Administration (“NMPA”) in China and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval for any product candidate, such events could have a materially adverse impact on the Company’s business.</span></div>
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-452200000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-360200000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	311700000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	383200000	usd
CY2019Q4	adr	Class Of Warrant Or Right Number Of Tranches ClassOfWarrantOrRightNumberOfTranches	3	tranche
CY2021Q1	adr	Class Of Warrant Or Right Number Of Tranches ClassOfWarrantOrRightNumberOfTranches	3	tranche
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	234086000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1221000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	232866000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	155018000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	55000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	155067000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1175000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	208441000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	46000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	14952000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1221000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	6000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	4980000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	6000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	4980000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	215939000	usd
CY2022Q3	adr	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne	16927000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	150087000	usd
CY2021Q4	adr	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne	4980000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4347000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2488000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1212000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	606000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3135000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1882000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	300000	usd
	us-gaap	Depreciation Depreciation	700000	usd
CY2021Q3	us-gaap	Depreciation Depreciation	100000	usd
	us-gaap	Depreciation Depreciation	300000	usd
CY2022Q3	adr	Prepaid Rent And Supplies PrepaidRentAndSupplies	1592000	usd
CY2021Q4	adr	Prepaid Rent And Supplies PrepaidRentAndSupplies	1499000	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	907000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	7378000	usd
CY2022Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	51000	usd
CY2021Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	3000	usd
CY2022Q3	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2093000	usd
CY2021Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1176000	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	474000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	298000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5117000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10354000	usd
CY2022Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4801000	usd
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2309000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4949000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3625000	usd
CY2022Q3	adr	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	7968000	usd
CY2021Q4	adr	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	3925000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	153000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	117000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17871000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9976000	usd
CY2021Q4	us-gaap	Other Commitment OtherCommitment	0	usd
CY2022Q3	us-gaap	Other Commitment OtherCommitment	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-21897000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-13112000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-92014000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-92014000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-175105000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-175105000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108353831	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108353831	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20690908	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20690908	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107854547	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107854547	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107854547	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107854547	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20549310	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20549310	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20549310	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20549310	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.52
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.52
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.52
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.52

Files In Submission

Name	View Source	Status
0001831283-22-000075-index-headers.html	Edgar Link	pending
0001831283-22-000075-index.html	Edgar Link	pending
0001831283-22-000075.txt	Edgar Link	pending
0001831283-22-000075-xbrl.zip	Edgar Link	pending
adr-20220930.htm	Edgar Link	pending
adr-20220930.xsd	Edgar Link	pending
adr-20220930_g1.gif	Edgar Link	pending
exhibit101-amendmentno1tol.htm	Edgar Link	pending
exhibit311-certificationof.htm	Edgar Link	pending
exhibit312-certificationof.htm	Edgar Link	pending
exhibit321-certificationof.htm	Edgar Link	pending
adr-20220930_cal.xml	Edgar Link	unprocessable
adr-20220930_def.xml	Edgar Link	unprocessable
adr-20220930_lab.xml	Edgar Link	unprocessable
adr-20220930_pre.xml	Edgar Link	unprocessable
adr-20220930_htm.xml	Edgar Link	completed
exhibit322-certificationof.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LIANY
LianBio Stock $liany

2022 Q4 Form 10-Q Financial Statement

#000183128322000075 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LIANY LianBio Stock $liany

2022 Q4 Form 10-Q Financial Statement

#000183128322000075 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LIANY
LianBio Stock $liany